March 29th 2023
Among persons with prediabetes who reverted to normoglycemia, only those who remained physically active saw a reduced risk of all-cause death, study authors report.
March 27th 2023
Wrist-worn Devices Prove Cost-effective for AF Screening of 30 Million in Economic SimulationAugust 10th 2022
Screening for atrial fibrillation with 6 wrist-worn wearable devices proved more cost effective than no screening and had greater relative benefit than using traditional modalities.
Early Rhythm Control May Not be as Effective in Adults with Newly Diagnosed Atrial FibrillationJuly 21st 2022
Early rhythm control reduced CV complications regardless of AF pattern but for patients with a first AF diagnosis, risks for hospitalization and ACS were higher after early rhythm therapy.
Statin Use Slowed Progression of Arterial Stiffness in High-risk Patients Followed for Nearly 5 YearsJune 27th 2022
Statin-treated patients at high atherosclerotic risk experienced significantly slower progression of arterial stiffness vs those not taking statins in a cohort of more than 5000 patients.
Finerenone Cardiorenal Effects in T2D Consistent Across Baseline HbA1c, Disease DurationJune 7th 2022
ADA 2022: The protective effect of finerenone on cardiovascular and renal outcomes was not affected by initial HbA1c levels or T2D duration in analysis of data from the FIDELITY pooled cohort.
Empagliflozin More Effective to Reduce Risk of Heart Failure Hospitalization vs DPP-4 Inhibitors, GLP-1 Receptor AgonistsJune 6th 2022
ADA 2022: In a real-world study of nearly half a million adults with T2D followed for 5 years, the SGLT-2 inhibitor surpassed both other classes used in routine clinical care.